SCHEMBL4127918

SCHEMBL4127918

COc1ccc(F)cc1-c1ccc(O)c(/C=C2/SC(Nc3ccc(C(C(=O)O)N4CCN(C)CC4)cc3)=NC2=O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 4/20 0.39
CDK9 P50750 4/20 0.39
MCHR1 Q99705 1/20 0.34
PIN1 Q13526 1/20 0.33
DYRK3 O43781 2/20 0.33
DYRK1A Q13627 2/20 0.33
DYRK2 Q92630 2/20 0.33
DYRK1B Q9Y463 2/20 0.33
CTSA P10619 2/20 0.33
PIM1 P11309 1/20 0.33
NPY2R P49146 1/20 0.33
CLK1 P49759 1/20 0.33
CLK2 P49760 1/20 0.33
CLK3 P49761 1/20 0.33
GSK3B P49841 1/20 0.33
CLK4 Q9HAZ1 1/20 0.33
ERN1 O75460 1/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
TDP1 Q9NUW8 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4127922 1.00 CCNT1 (0.39) CCNT1CDK9MCHR1PIN1DYRK3
SCHEMBL4132809 0.80 MMEL1 (0.35) CCNT1CDK9CTSAERN1MEN1
SCHEMBL4132813 0.80 MMEL1 (0.35) CCNT1CDK9CTSAERN1MEN1
SCHEMBL4132689 0.80 CTSA (0.36) PIN1CTSAERN1MEN1KMT2A
SCHEMBL4132687 0.80 CTSA (0.36) PIN1CTSAERN1MEN1KMT2A
SCHEMBL4133913 0.78 CTSA (0.36) CTSAERN1MEN1KMT2ATDP1
SCHEMBL4133910 0.78 CTSA (0.36) CTSAERN1MEN1KMT2ATDP1
SCHEMBL13746842 0.69 MEN1 (0.39) MEN1KMT2ATDP1HPGDMAPT
SCHEMBL4343587 0.66 AMY1A (0.59) MCHR1MEN1KMT2AHPGDMAPT
SCHEMBL13629855 0.66 AMY1A (0.59) MCHR1MEN1KMT2AHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ CCNT1 3249/4885CDK9 1690/4885MCHR1 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.